SAB Biotherapeutics (SABS) Income towards Parent Company (2021 - 2025)
Historic Income towards Parent Company for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to -$12.1 million.
- SAB Biotherapeutics' Income towards Parent Company fell 1659.63% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.6 million, marking a year-over-year increase of 657.27%. This contributed to the annual value of -$41.9 million for FY2024, which is 59.45% up from last year.
- Latest data reveals that SAB Biotherapeutics reported Income towards Parent Company of -$12.1 million as of Q3 2025, which was down 1659.63% from -$9.8 million recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Income towards Parent Company ranged from a high of $1.4 million in Q1 2021 and a low of -$22.9 million during Q4 2023
- Moreover, its 5-year median value for Income towards Parent Company was -$7.3 million (2024), whereas its average is -$7.5 million.
- As far as peak fluctuations go, SAB Biotherapeutics' Income towards Parent Company plummeted by 84592.72% in 2023, and later skyrocketed by 5649.72% in 2024.
- Quarter analysis of 5 years shows SAB Biotherapeutics' Income towards Parent Company stood at -$11.6 million in 2021, then soared by 32.05% to -$7.8 million in 2022, then crashed by 191.21% to -$22.9 million in 2023, then skyrocketed by 56.5% to -$9.9 million in 2024, then decreased by 21.36% to -$12.1 million in 2025.
- Its last three reported values are -$12.1 million in Q3 2025, -$9.8 million for Q2 2025, and -$10.8 million during Q1 2025.